Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Complementary Medicine and Therapies
Published in: BMC Complementary Medicine and Therapies 1/2023

Open Access 01-12-2023 | Rheumatoid Arthritis | Research

Benefit-risk assessment of traditional Chinese medicine preparations of sinomenine using multicriteria decision analysis (MCDA) for patients with rheumatoid arthritis

Authors: Gao Xiang, Min Gao, Huirong Qin, Xiaolan Shen, Huilian Huang, Xiaoqiang Hou, Zhitao Feng

Published in: BMC Complementary Medicine and Therapies | Issue 1/2023

Login to get access

Abstract

Objective

A multicriteria decision analysis (MCDA) model was used to evaluate the benefits and risks of traditional Chinese medicine preparations of sinomenine alone or in combination with conventional drugs in the treatment of rheumatoid arthritis (RA) and to provide a basis for the rational clinical application of sinomenine.

Methods

A study search was performed using six major databases, and Review Manager 5.3 was used for data analysis. Then, an MCDA model evaluation system was established for the treatment of RA with sinomenine preparations, and the benefit values, risk values, and total benefit-risk values of sinomenine preparations alone or in combination with conventional drugs were calculated using Hiview 3.2 software. Finally, Monte Carlo simulations were performed using Crystal Ball embedded in Excel software to calculate the 95% confidence intervals (95% CI), and the probability of the differences between the 2 drug regimens was determined to optimize the evaluation results.

Results

Forty-four randomized controlled trials (RCTs) were included. Quantitative assessment of the MCDA model showed that the sinomenine preparation alone offered less benefits than when combined with conventional drugs with a benefit difference of 20 (95% CI 3.06, 35.71). However, the risk of the combination was significantly lower with a risk difference of 13(95% CI -10.26, 27.52). The total value of the benefit-risk of sinomenine alone and in combination with conventional drugs was 46 and 53 at 60% and 40% of the benefit-risk ratio of the two dosing regimens, respectively, with a difference of 7 (95% CI -4.26, 22.12). The probability that the comprehensive score of the combined regimen is greater than that of sinomenine alone is 90.1%, and the evaluation was steady.

Conclusion

The benefit-risk of the combined application regimen of sinomenine is greater than that of sinomenine alone.
Literature
1.
2.
3.
Sun Y, Huang Y, Chen T, Li X, Chen J, Wang Z, Lin K, Gao Y, He L. Effect of downregulation of serum MMP-3 levels by traditional Chinese medicine ingredients combined with methotrexate on the progression of bone injury in patients with rheumatoid arthritis: A protocol for a systematic review and meta-analysis. Medicine. 2020;99(43):e22841. https://​doi.​org/​10.​1097/​MD.​0000000000022841​.CrossRef
4.
5.
6.
Xu W, Chen S, Wang X, Wu H, Tahara K, Tanaka S, Sugiyama K, Yamada H, Sawada T, Hirano T. Effects of sinomenine on the proliferation, cytokine production, and regulatory T-cell frequency in peripheral blood mononuclear cells of rheumatoid arthritis patients. Drug Dev Res. 2021;82(2):251–8. https://​doi.​org/​10.​1002/​ddr.​21748.CrossRef
7.
8.
9.
10.
11.
12.
Zhu J, Chen P. 30 cases of rheumatoid arthritis treated by integrated Chinese and Western medicine. Fujian J Tradit Chin Med. 2001;04:22–4.
13.
Ji H, Zhu Z. 30 cases of rheumatoid arthritis treated with low dose Zhengqing Fengtongning combined with methotrexate. Herald of Med. 2006;01:37–8.
14.
Yang B, Liu X. The Clinical Curative effect of Zhengqingfengtongning Combined with Methotrexate in Treatment of Rheumatoid Arthritis. China J Pharma Econ. 2015;10(05):53–5.
15.
16.
17.
Wu Y. Clinical observation of 40 cases of rheumatoid arthritis treated with low dose methotrexate and Zhengqing Fengtongning. J New Chinese Med. 2003;01:40–1.
18.
19.
Xia Y, Tu S, Hu Y, Wang Y, Chen Z, Liu Y. Clinical Observation of Effect of Methotrexate Combined with Zhengqingfengtongning in Treating Active Rheumatoid Arthritis Based on Syndrome Differentiation. Res Integ Trad Chin West Med. 2012;4(05):225–8.
20.
21.
22.
Yu Y, Chi S. Clinical observation of Zhengqing Fengtongning combined with sulfasalazine in the treatment of rheumatoid arthritis. Clin Med China. 2005;09:808–9.
23.
24.
25.
26.
Zhang Q. Clinical observation on 52 cases of rheumatoid arthritis treated by Zhengqing Fengtongning. Fujian J Tradit Ch Med. 1998;02:20–1.
27.
Yang X, Yang J. Clinical observation on 118 cases of rheumatoid arthritis treated by Zhengqing Fengtongning. J Chinese Phys. 2003;S1:297–8.
28.
Huang Z, Wang N. Clinical observation on treatment of rheumatoid arthritis with zhengqing fengtongning retard tablets. Hebei Med J. 2010;32(01):59–60.
29.
Liu W, Liu X, Liu B. Clinical observation on treatment of rheumatoid arthritis with Zhengqing Fengtongning Retard Tablets :a report of 60 cases. J Chin Integ Med. 2006;02:201–2.CrossRef
30.
Zhang Z, Shen J, Liu K. Clinical observation on treatment of senile rheumatoid arthritis by Zhengqing Fengtongning. J Tradit Chin Orthop Traumatol. 2002;14(02):12–13+63.
31.
Ma H, Liang X. Clinical Observation on Zhengqing Fengtongning Sustained-Release Tablets Combined with Methotrexate in the Treatment of Rheumatoid Arthritis. Chin Med Modern Distance Educ Cina. 2020;18(04):112–4.
32.
33.
Lin X, Cai X, Ye J. The clinical observition on Sinomenine for Rheumatoid Arthritis. J Hunan Unive Chinese Med. 2009;29(08):52–4.
34.
Shen X, Li H. Clinical studies on Zhengqingfengtong ning in treatment of rheumatoid arthritis. J Anhui Tradit Chin Med College. 2005;01:9–11.
35.
36.
37.
Huang G, Li J, Huang Y, Huang D, Tang L, Zhang S, Li Q. The Clinical Study on Sinomenine for100 Patients with Rheumatoid Arthritis. J Emerg Tradit Chin Med. 2007;16(04):416–417+421.
38.
39.
Lao Z. Combination of sinomenine and methotrexate in the treatment of rheumatoid arthritis. Chin J New Drugs Clin Remed. 2000;04:254–6.
40.
Li C, Gao Y, Fan C, Chen Q. Comparative observation of clinical efficacy of Zhengqing Fengtongning and Tripterygium wilfordii glycosides in treating rheumatoid arthritis. The Med Forum. 2005;06:526–7.
41.
Gao J, Zhang Q, Ji N, Deng D, Wang H, Tong D. Comparison of sinomenine alone or with chloroquine and Tripterygium glycosides in the treatment of rheumatoid arthritis. Chin J New Drugs and Clin Remed. 1999;04:215–7.
42.
43.
44.
Li Y, Feng X, Zhang S, Li C. Effects of sinomenine combined with methotrexate on rheumatoid arthritis. Pract Pharm Clin Remed. 2008;05:285–7.
45.
Dai L, Song X, Wang J. Effects of sinomenine combined with methotrexate on serum inflammatory factors in patients with rheumatoid arthritis and its safety. Shaanxi Med J. 2018;47(12):1580–3.
46.
47.
48.
Yang D, Zheng X. Observation on the curative effect of Zhengqing Fengtongning sustained-release tablets in the treatment of rheumatoid arthritis. Drug evaluation. 2005;02:152–3.
49.
Su J. A Randomized Controlled Ctudy of Cinomenine Custained - release Tablets Combined With Western Medicine in the Treatment of Rheumatoid Arthritis. J Pract Tradit Chin Intern Med. 2013;27(04):104–6.
50.
Zhang G, Fu Z, Wang K, Liu X. The study of Zhengqinfengtongning on expression of chemokine RANTES in patients with rheumatoid arthritis. Proceed Clin Med. 2005;12:893–5.
51.
52.
Hu Q, Guan X, Lian Y, Lei L, Tao L. Therapeutic Effect Observations of Leflunomi de and Methopterin Combined with Zhengqing Fengtongning in Treat ment of Rheumatoid Arthritis. J Modern Clin Med. 2010;36(05):338–40.
53.
Yang C. Therapeutic effect of methotrexate combined with Traditional Chinese medicine in the treatment of rheumatoid arthritis. Chin Prim Health Care. 2009;23(10):130–1.
54.
55.
Lin Z, Dai L, Zheng L, Dai Y, Li T. Value of “ZhengqingFengtongning”onTreatment of Rheumatoid Arthriti. Clin J Med Officer. 2007;02:245–7.
56.
57.
Moore A, Crossley A, Ng B, Phillips L, Sancak Ö, Rainsford KD. Use of multicriteria decision analysis for assessing the benefit and risk of over-the-counter analgesics. J Pharm Pharmacol. 2017;69(10):1364–73.CrossRef
58.
Croia C, Bursi R, Sutera D, Petrelli F, Alunno A, Puxeddu I. One year in review 2019: pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol. 2019;37(3):347–57.
59.
60.
61.
62.
63.
Metadata
Title
Benefit-risk assessment of traditional Chinese medicine preparations of sinomenine using multicriteria decision analysis (MCDA) for patients with rheumatoid arthritis
Authors
Gao Xiang
Min Gao
Huirong Qin
Xiaolan Shen
Huilian Huang
Xiaoqiang Hou
Zhitao Feng
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2023
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-023-03864-6

Other articles of this Issue 1/2023

BMC Complementary Medicine and Therapies 1/2023 Go to the issue

Research

Screening of key functional components of Taohong Siwu Decoction on ischemic stroke treatment based on multiobjective optimization approach and experimental validation

Study Protocol

Effect of group-based acceptance and commitment therapy on older stroke survivors: study protocol for a randomized controlled trial

Research

Angiotensin converting enzyme (ACE) inhibitors activity from purified compounds Fructus Phaleria macrocarpa (Scheff) Boerl

Research

Knowledge and experiences of families regarding amber necklaces

Research

Shenkang protects renal function in diabetic rats by preserving nephrin expression

Research

Sweet-type star fruit supplementation controls oxidative stress status and enhances the community walking capacity among elderly Thai